A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Epcoritamab (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man; Registrational; Therapeutic Use
Acronyms EPCORE NHL-1
Sponsors Genmab

09 Dec 2024 Results ( As of April 21, 2023) assessing long-term efficacy and safety Epcoritamab in relapsed/refractory large B-cell lymphoma presented in the AbbVie Media Release.
09 Dec 2024 According to an AbbVie media release, data from this study were published at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH).
01 Dec 2024 Results published in the Leukemia

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com